Skip to main content

Drug Safety

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

MedPage Today
Mar 23, 2023

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.

Read Article

Updated AAV Treatment Recommendations

Mar 22, 2023

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging.

Read Article

Our old friend, hydroxychloroquine

Mar 22, 2023

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France,

Read Article

Metformin Reduces Osteoarthritis Risk

MedPage Today
Mar 21, 2023

Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.

In a retrospective cohort study of nearly 21,000 adults with diabetes, those who were taking metformin saw a 24% lower risk for developing OA compared with those taking a

Read Article
Reassuring data by Dr. Laurent Arnaud on HCQ - arrhythmia risk from HCQ similar to general population @RheumNow #RNL2023
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023
Extension PEXIVAS study in ANCA vasculitis pts with severe DAH - no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH - note difference in curve @RheumNow #RNL2023
Biosimilar to biosimilar switching of Infliximab , ⁦@RheumNow⁩ Kavanaugh #RNL2023 Communications is a key always. Discuss with your patient always, and show them the data.
How does HCQ work @Lupusreference in #RNL2023 HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN HCQ works as base to increase lysosomal pH and affect cellular function @RheumNow
Smoking and SLE Smoking increases SLE activity Smoking decreases HCQ efficacy Skin response on HCQ down 50% in smokers 🚬 @Lupusreference #RNL2023 @RheumNow
✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023 @RheumNow ⬇️
SRI Responders more likely able to reduce prednisone and far Serological improvement SF-36 Fatigue by Richard Furie #RNL2023 ⁦@RheumNow⁩
#RNL2023 Year in Review COMPLETE-PsA: DMARDs for PsA! LEF+MTX better than MTX alone, 78 total patients PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO More treatment discontinuations (10 vs 3) in combo group due to GI intolerance @RheumNow
Should we be measuring HCQ levels? - note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels - adjust dose for pts with renal impairment @RheumNow #RNL2023
#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow
Could MTX every other week dosing be an option in patients with stable disease..? #RNL2023
Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow
✅ RheumNow Live 2023 #RNL2023 @RheumNow Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus?
#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023
Do you stop MTX on patients on bDMARD? MTX decrease anti-drug antibodies on patients on infliximab - increases drug duration. Similar seen with new combination usage with pelogloticase Joel Kremer MD #RhuemNow @RheumNow
How do you wean MTX? Consider every other week dosing as options - supported by 2 randomized studies from 1995 and 1999 Option to lower weekly dosing in patients that want to take less often Joel Kremer #RNL2023 @RheumNow
Do and don’t around MTX , Dr.Kremer approach to MTX #RNL2023 ⁦@RheumNow⁩
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package).